retatrutide phase 2 trial obesity nejm 2023 of for GLP-1 Receptor Agonists | New

Summary: Stacking retatrutide and tesamorelin is not supported by any clinical evidence, carries significant safety risks, and involves two agents that are unlicensed in the UK

All of these drugs belong to a class of medications known as GLP-1 receptor agonists, which mimic a hormone in your body called glucagon-like peptide-1 (GLP-1)

Most safety concerns with Retatrutide involve manageable side effects that improve with time and appropriate dose escalation

This $99 add-on maps your metabolism across 14 peptide pathways and 150+ genetic insights, revealing whether your response pattern matches expected timelines or suggests personalized optimization opportunities